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OBJECTIVES: Attention-deﬁcit hyperactivity disorder (ADHD)
is a common disorder that is associated with broad functional
impairment among both children and adults. The purpose of this
project was to review literature on the economic costs of ADHD,
as well as potential economic beneﬁts of treating this condition.
METHODS: A literature search was performed using MEDLINE
to identify all published articles on the economic implications 
of ADHD, and authors were contacted to locate conference
abstracts and articles in press that were not yet indexed. In total,
22 relevant items were located including published original
studies, economic review articles, conference presentations, and
reports available on the Internet. RESULTS: Results of medical
cost studies consistently indicated that children with ADHD had
higher annual medical costs than either matched controls 
(difference ranged from $503 to $1343) or non-matched con-
trols (difference ranged from $207 to $1560) without ADHD.
Two studies of adult samples found similar results. A limited
number of studies have examined other economic implications
of ADHD including costs to families; costs of criminality among
individuals with ADHD; costs related to common psychiatric
and medical comorbidities of ADHD; and costs of accidents
among individuals with ADHD. Treatment cost-effectiveness
studies have primarily focused on methylphenidate, which is a
cost-effective treatment option with cost-effectiveness ratios
ranging from $15,509 to $27,766 per quality-adjusted life year
(QALY) gained. CONCLUSIONS: A growing body of literature,
primarily published in the United States, has demonstrated that
ADHD places a substantial economic burden on patients, fami-
lies, and third-party payers. Recognition, diagnosis and treat-
ment of ADHD are increasing in Europe and Australia, and
future studies may document the economic burden of ADHD in
these areas. As new treatments are introduced, it will be impor-
tant to evaluate their cost-effectiveness to provide an indication
of their potential value.
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ESTIMATING THE BUDGET IMPACT OF QUETIAPINE 
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OBJECTIVES: To develop a tool to allow estimation of the
budget impact of treatments for acute mania in bipolar I disor-
der from a US health care payer perspective. METHODS: Course
of each individual is simulated beginning with hospitalization.
Discharge depends on the level of symptoms as measured by the
Young Mania Rating Scale (YMRS). The effect of treatment is
determined using time-dependent regression equations derived
from trial data, and decision rules obtained from clinical experts.
Outcomes include: time to response and symptom resolution;
proportion of subjects reaching each outcome; number of
adverse events. Medical care costs were obtained from hospital
discharge databases, the National Medicare Physician Fee Sched-
ule and RedBook. Different scenarios are examined, each
describing the proportion of subjects on the various treatments
(lithium; divalproex sodium; olanzapine, risperidone and queti-
apine—monotherapy and in combination with lithium). The
base case scenario was derived from the distribution of treat-
ments observed in a state Medicaid population. Subjects may
switch treatment at any point, but analyses are intention-to-treat
over 100 days, corresponding to follow-up in mania trials.
RESULTS: Scenarios with a greater proportion of quetiapine
users (5% vs. 40% and 100%) result in a smaller impact on the
health care budget ($6912, $6277 and $5525 per patient, respec-
tively) and improvements in patient outcomes (e.g., 43%, 47%
and 54% responding at day 21; 74%, 77% and 80% remitting
by day 84). Quetiapine is cost-saving compared to olanzapine
(about $250 per patient), mainly due to fewer side-effects. Sen-
sitivity analyses showed the budget impact is inﬂuenced by drug
prices, discharge criteria and side-effect management. CON-
CLUSIONS: Results suggest that increased use of quetiapine for
mania in the US is economically sound and will improve health
outcomes. In addition, this model illustrates that discrete event
simulation is a very useful and versatile tool for budget impact
analyses.
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MENTAL HEALTH COST COMPARISON AMONG PATIENTS
WITH BIPOLAR DISORDER TREATED WITH RISPERIDONE
VERSUS OLANZAPINE OR QUETIAPINE IN A MANAGED
CARE SETTING: A PROPENSITY-MATCHED COHORT STUDY
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OBJECTIVE: To compare mental health-related costs among
patients with bipolar disorder treated with atypical antipsy-
chotics in a managed care setting. METHODS: This was a ret-
rospective cohort study using administrative claims data from a
national managed care organization. Participants initiated treat-
ment with risperidone, olanzapine, or quetiapine between July
1, 2000 and December 31, 2002, and had a bipolar disorder
diagnosis within six months of the index prescription for an
atypical antipsychotic. Subjects treated with more than one
antipsychotic at index were excluded. Subjects were matched one
to one on the propensity to receive risperidone using a score esti-
mated from a logistic regression model, which included age,
gender, psychiatric comorbidities, plan type, geographic region
and mood stabilizer use. Once matched, 12 months of follow-
up mental health-related costs and utilization data were com-
pared using univariate statistics. RESULTS: The olanzapine
cohort accounted for half of the study patients (n = 1660, 50%)
followed by the risperidone (n = 951, 29%) and quetiapine
cohorts (n = 699, 21%). After adjusting for treatment selection
bias through propensity matching, risperidone- and olanzapine-
treated subjects had similar mental health costs ($5728 vs.
$5908, respectively, NS). The cost of psychotropic therapy was
signiﬁcantly higher for the olanzapine versus risperidone cohort
($3363 vs. $2969, p = 0.001) and was the only signiﬁcant dif-
ference between these cohorts. Risperidone patients had signiﬁ-
cantly lower mental health costs compared to subjects treated
with quetiapine ($5666 vs. $6579, respectively, p = 0.007). Sub-
jects treated with risperidone also had signiﬁcantly lower psy-
chotropic therapy costs compared to quetiapine subjects ($2929
vs. $3492 respectively, p < 0.0001). CONCLUSION: In a
managed care setting, patients with bipolar disorder treated with
risperidone had similar mental health costs compared to patients
receiving olanzapine, and lower mental health costs compared to
those treated with quetiapine. This study provides important
comparative information on the real world cost of bipolar
patients treated with atypical antipsychotics.
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OBJECTIVE: Hospitalization and inpatient charge comparisons
for bipolar and manic patients receiving atypical and conven-
tional antipsychotics. METHODS: Analysis of a claims database
(1999–2003) representing 50 million US insured patients 
identiﬁed 12,835 treatment episodes of monotherapy for bipolar
and manic disorders with atypicals (risperidone, olanzapine, 
quetiapine, ziprasidone) and conventionals (haloperidol, 
perphenazine, thioridazine, thiothixene). Hazard ratios (HR) for
hospitalization risks were estimated with Cox regression adjust-
ing for patient characteristics. Inpatient charges were based on
these estimates and estimated hospital stays. RESULTS: Risperi-
done and olanzapine had signiﬁcantly (P < 0.05) higher risks of
hospitalization than quetiapine (HR 1.185 and 1.187, respec-
tively) and trended (P < 0.10) toward higher risks than ziprasi-
done (HR 1.443 and 1.447, respectively), translating into higher
inpatient charges of $194–$389 per patient per year. On com-
paring the atypicals in manic rapid cyclers (a high hospitaliza-
tion subgroup), risperidone had a signiﬁcantly (P < 0.05) higher
risk of hospitalization than olanzapine (HR = 3.309) and olan-
zapine trended (P < 0.10) toward longer stays than quetiapine
(7.56 days longer), both translating into higher inpatient charges.
CONCLUSION: In treating bipolar and manic disorders, risperi-
done and olanzapine may have higher risks of hospitalization
than quetiapine. In treating manic rapid cyclers, olanzapine may
have a lower risk of hospitalization than risperidone, but longer
stays than quetiapine.
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OBJECTIVES: To determine the prevalence of patients with
bipolar disorder (BD) and compare their annual health care costs
to patients with other mental health disorders, in a large United
States managed care organization. METHODS: This was a ret-
rospective claims analysis of approximately 1.4 million com-
mercial health plan members with mental health beneﬁts. Adults
with a primary or secondary diagnosis of a mental health disor-
der in 2002 were identiﬁed and the prevalence of BD calculated.
Those continuously enrolled throughout 2003 (follow-up
period) were stratiﬁed to one of two cohorts: “BD” (Bipolar 
Disorder) or “OMHD” (Other Mental Health Disorder). Patient
demographics, pharmacological treatments, and health care
charges were compared between cohorts, adjusting for potential
confounding factors of age, gender, and comorbidity. RESULTS:
During 2002, there were 6581 patients (mean age 40.3 years;
65.7% female) with BD, yielding an overall prevalence rate of
4.68 per 1000 members. Among the 64,434 continuously
enrolled mental disorder patients in 2003, 3,043 (4.7%) were
classiﬁed as “BD” and 61,391 (95.3%) were classiﬁed as
“OMHD”. Patients in the “BD” group were younger (41.7 vs.
43.0 years; p < 0.0001) with higher Charlson comorbidity index
(0.56 vs. 0.47; p < 0.0001) compared to the “OMHD” group.
Less than half (38.3%) of “BD” patients received a mood sta-
bilizer (lithium, valproate, or carbamazepine) and 20.0%
received no psychotropic medication. Adjusted pharmacy,
medical, and total health care charges were higher in the “BD”
group compared to “OMHD”: $2641 vs. $1071, $13,419 vs.
$8422, and $16,059 vs. $9493 respectively (p < 0.0001 for all
three comparisons). CONCLUSIONS: Compared to the national
prevalence rate of 1%, BD may be under-diagnosed, and phar-
macologic therapy underutilized within managed care. Patients
with BD incurred greater health care charges compared to other
mental health disorders. Efforts aimed at improving diagnosis
and treatment of BD may optimize care and cost of managing
this patient population.
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OBJECTIVES: Existing research offers little empirical evidence
to support national practice guidelines about antidepressant use
in patients with bipolar disorder. This study assessed the clinical
and economic impact of second-generation antidepressant use
for bipolar depressed adult patients. METHODS: Bipolar disor-
der subjects were identiﬁed with a new depressive episode in a
national managed-care plan between January, 1998 and Decem-
ber, 2002. In total, 3737 patients were deﬁned with the index of
interested medication initiation and at least three-months pre-
index and 12-month post-index continuous enrollments. Logit
model with a difference-in-difference approach was employed to
identify the relationship between treatment types (antidepressant
monotherapy, mood stabilizer monotherapy, and antidepressant-
mood stabilizer combination therapy) and the probability of
mania-related visits. In addition, negative binomial model and
log-transformed OLS model were used to predict number of
depression-related visits and health care costs respectively.
RESULTS: Probability of mania-related visits increased signiﬁ-
cantly from pre-index to post-index period with odds ratio 2.40
(95% CI: 1.52–3.79) for antidepressant monotherapy compared
to mood stabilizer monotherapy, controlling for time ﬁxed-effect,
demographics, clinical-related and health-related variables.
However no signiﬁcant difference was identiﬁed between com-
bination therapy and mood stabilizer monotherapy. Patients 
with antidepressant monotherapy and combination therapy had
signiﬁcantly lower incidence rate ratios of 0.68 (95% CI:
0.56–0.82) and 0.65 (95% CI: 0.52–0.81) respectively for
depression-related visits, but signiﬁcantly higher bipolar-related
costs (232% and 72% respectively) compared to patients with
mood stabilizer monotherapy. CONCLUSIONS: This study adds
to the literature of bipolar depression treatment by providing
empirical evidence at the national level to support the current
practice guidelines. Second-generation antidepressant monother-
apy indicated a risk of induced manic-switching, which can be
costly in terms of overall health care resources. Since the safety
and efﬁcacy of antidepressants in bipolar disorder have not been
ﬁrmly established, medical practitioners and policy makers
should take precautions regarding the appropriate use of new
antidepressants.
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OBJECTIVES: To assess the clinical outcomes of modern
second-generation antidepressant medication use in bipolar dis-
order, with a focus on the risk of induced manic-switching for
adult patients with bipolar depression. METHODS: Bipolar dis-
order subjects were identiﬁed with a new depressive episode in
a national managed care plan between January, 1998 and
December, 2002. A case-control study design was applied for
which cases and controls were deﬁned by whether having mania-
related visits in the 12-months continuous enrollment after
